Laurel-Worthy: How Laurus Labs Leaped To 3606% Returns
If you had invested ₹1L in Laurus Labs in September 2019, then you could have had a whopping amount of ₹37,06,944 today! This multibagger showed 36x growth in 3 years. Let’s take a quick look at the company.
⚕️ Stock Name: Laurus Labs Ltd.
⚕️ NSE: $LAURUSLABS
⭐ About The Company
Laurus Labs is a pharmaceutical and biotechnology company which makes Active Pharmaceuticals Ingredients (API) and also intermediates. It aims to improve the quality of life for millions around the world. The company works with the top 10 generic pharmaceutical companies in the world and sells its APIs in 56 countries. It majorly focuses on antiretroviral, Hepatitis C and Oncology drugs.
🧪 Research & Development
The pharma conglomerate has a research team of over 750 scientists for research & development, in key areas with significant demand & growth potential. It has filed 322 patents out of which they own 184. It has a dedicated R&D centre in Hyderabad, which is approved by major regulatory authorities like USFDA, PMDA, KFDA, Department of Scientific and Industrial Research, Ministry of Science and Technology of India (DSIR) and others.
It has commercialised more than 60 products since its inception across three distinct business units:
💉 Generics API
💉 Generics FDF
With world-class manufacturing facilities capable of large-scale commercial API production, it is positioned as a key supplier for pharmaceutical companies seeking to leverage its technical expertise and cost-effective manufacturing capabilities. Its state-of-the-art Fixed Dosage Formulations (FDF) manufacturing facility has a capacity of one billion tablets per year which has the capacity for 5 billion tablets per year.
💰 Stock Value
💵 Laurus Labs has had 1 stock split
📅 On 29th September 2020 in the ratio of 10:2 (1408 x 5)
The effective number of shares went from 1408 to 7040
💵 On October 4, 2019, the shares of the company were trading at ₹71, while they were priced at ₹512.35 as of October 03, 2022.